BioLineRx (BLRX) –
-
Form 6-K BioLineRx Ltd. For: Apr 17
-
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
-
Form 6-K BioLineRx Ltd. For: Apr 10
-
BioLineRx (BLRX) Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
-
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
-
Form 6-K BioLineRx Ltd. For: Apr 01
-
Form 424B5 BioLineRx Ltd.
-
BioLineRx (BLRX) Announces 7.5M Share Offering at $0.80/sh
-
BioLineRx Announces $6 Million Registered Direct Offering
-
Form 20-F/A BioLineRx Ltd. For: Dec 31
-
Form 20-F BioLineRx Ltd. For: Dec 31
-
Form 6-K BioLineRx Ltd. For: Mar 26
-
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
-
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
-
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
-
Form 6-K BioLineRx Ltd. For: Mar 04
-
BioLineRx (BLRX) Receives Patent for Method of Manufacturing Motixafortide
-
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
-
Form 6-K BioLineRx Ltd. For: Feb 28
-
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
-
Form 6-K BioLineRx Ltd. For: Feb 16
-
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetin
-
Form EFFECT BioLineRx Ltd.
-
BioLineRx (BLRX) Files $250M Mixed Shelf
-
Form S-8 BioLineRx Ltd.
-
Form F-3 BioLineRx Ltd.
-
Form 6-K BioLineRx Ltd. For: Dec 21
-
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
-
Form 6-K BioLineRx Ltd. For: Dec 12
-
Form 6-K BioLineRx Ltd. For: Nov 20
-
BioLineRx (BLRX) Tops Q3 EPS by 20c
-
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
-
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
-
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
-
Form SC 13D BioLineRx Ltd. Filed by: Hong Seng Technology Ltd
-
Form 6-K BioLineRx Ltd. For: Oct 12
-
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
-
Form 6-K BioLineRx Ltd. For: Sep 28
-
BioLineRx (BLRX) Reports Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide
-
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
-
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
-
BioLineRx (BLRX) PT Raised to $21 at H.C. Wainwright following APHEXDA approval
-
Form 6-K BioLineRx Ltd. For: Sep 11
-
BioLineRx (BLRX) Announces FDA Approval of APHEXDA in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with
-
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in P
-
BioLineRx (BLRX) Halted, News Pending
-
Form 6-K BioLineRx Ltd. For: Jun 30
-
BioLineRx (BLRX) Tops Q2 EPS by 7c
-
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
-
Form 6-K BioLineRx Ltd. For: Aug 30
Back to BLRX Stock Lookup
